Allakos Announces Proposed Public Offering of Common Stock
August 05, 2019 16:29 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Reports Second Quarter 2019 Financial Results
August 05, 2019 07:15 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)
August 05, 2019 07:00 ET
|
Allakos Inc.
Primary efficacy endpoint met with 95% reduction in gastrointestinal tissue eosinophils vs. 10% increase on placebo (p < 0.0001)Treatment response secondary endpoint met with 69% of AK002 treated...
Allakos Reports First Quarter 2019 Financial Results
May 08, 2019 08:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
May 07, 2019 16:01 ET
|
Allakos Inc.
-- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms -- -- Improvements also observed in atopic dermatitis, asthma and allergic rhinitis -- -- Conference...
Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
March 14, 2019 16:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
February 19, 2019 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
February 11, 2019 08:00 ET
|
Allakos Inc.
-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU...
Allakos to Host Investor Day on February 19 in New York City
February 04, 2019 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today...
Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
January 29, 2019 08:00 ET
|
Allakos Inc.
-- 82% (9 of 11) response rate in patients with cholinergic urticaria ---- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE...